IPSEN (OTCMKTS:IPSEY) Sees Significant Drop in Short Interest

IPSEN (OTCMKTS:IPSEY) saw a large decrease in short interest in September. As of September 15th, there was short interest totaling 41 shares, a decrease of 96.6% from the August 31st total of 1,214 shares. Based on an average daily trading volume, of 2,201 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are short sold.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Zacks Research upgraded IPSEN to a “hold” rating in a report on Friday, May 29th. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Finally, Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold”.

IPSEN Stock Performance

Shares of OTCMKTS IPSEY remained flat at $41.97 during trading hours on Thursday. 106 shares of the company traded hands, compared to its average volume of 611. IPSEN has a fifty-two week low of $32.02 and a fifty-two week high of $51.10. The business’s 50 day moving average is $46.15 and its 200 day moving average is $46.59.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.